JOHNSON & JOHNSON

NYSE: JNJ (Johnson & Johnson)

最近更新时间: 22分钟之前

278.59

-3.97 (-1.40%)

前收盘价格 282.55
成交量 2,933,954
预期市盈率 (P/E Forward) 23.84
价格/销量 (P/S) 7.03
股市价格/股市净资产 (P/B) 8.44
52周波幅
198.53 (-28%) — 290.25 (4%)
股息率 (DY TTM) 1.92%
营业毛利率 25.00%
营业利益率 (TTM) 28.26%
稀释每股收益 (EPS TTM) 9.34
季度收入增长率 (YOY) 5.80%
季度盈利增长率 (YOY) 18.20%
总债务/股东权益 (D/E MRQ) 66.90%
流动比率 (MRQ) 1.26
营业现金流 (OCF TTM) 24.78 B
杠杆自由现金流 (LFCF TTM) 16.80 B
资产报酬率 (ROA TTM) 7.77%
股东权益报酬率 (ROE TTM) 29.45%

AIStockmoo 评分

1.1
价值 30% -1.1
来自我们的 AI Insight 报告对预期回报与风险的评估。 参考
相对其盈利增长,估值偏高。 参考
当前股价隐含每年 18.3% 的盈利增长;公司业务可支撑约每年 14.4% 的增长。 参考
高于其一贯估值。 参考
负债低。盈利能力强。短期流动性偏紧。现金流为正。 参考
资本回报远高于资本成本。资本回报上升。 参考
时机 30% 2.9
来自我们对走势图的 AI 技术分析。 参考 NA
过去一年呈上升趋势。股价接近52周高点。 参考
近期出现看跌反转形态:看跌吞没。 参考
您持有期的趋势 参考 NA
市场情绪 20% 0.5
近期没有目标价,因此依据目标价的调整方向。 参考
近期新闻大多正面。 参考
聪明钱 20% 1.9
内部交易活动 参考 NA
机构在最新13F申报中净+1.23%的股份:2,328家增持,2,195家减持(截至30 Sep 2026的季度)。 参考
市场和行业状况中性。
市场环境偏谨慎。 参考
行业表现优于大市。
各支柱方向一致,评分因此加强。
不计入评分
股价高于其52周平均水平。5年来上涨。 参考
短、中、长期趋势均向上。短期动能上升。 参考
股价接近阻力位。 参考
最终评分 1.10

市场趋势

短期 中期
行业 Drug Manufacturers - General (US) 混合的 看涨
Drug Manufacturers - General (全球的) 混合的 看涨
股票 Johnson & Johnson 混合的 看涨

相关股票

股票 市值 DY P/E(TTM) P/B
JNJ - 1.92% - 8.44
PFE - 6.00% - 1.85
ABBV - 3.18% - -
NVO - 4.16% - 5.56
BMY - 4.36% - 5.54
GSK - 3.66% - 4.09

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

部门 Healthcare
行业 Drug Manufacturers - General
投资方式 Large Value
内部持股比例 0.06%
机构持股比例 74.08%

该时间范围内无数据。

该时间范围内无数据。

机构

机构持股比例: 86.20%

持仓变动 机构数 股数
增持 2,328 76,966,419
减持 2,195 55,308,255
新建仓 223 10,541,352
清仓 112 2,557,767

来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。

23 正面 4 负面 18 中性
日期 类型 细节
17 Nov 2026 Yahoo Finance Louisiana Appeals Court Upholds Millions in Damages in Mesothelioma Case Against Johnson & Johnson
DALLAS, November 17, 2026--An appeals court in Louisiana has upheld a multimillion verdict against Johnson & Johnson, in which a jury found that talc in its baby powder caused a New Orlean's woman's mesothelioma and death.
17 Nov 2026 Yahoo Finance Johnson & Johnson's Planned Ollin Biosciences Acquisition to Serve as Growth Driver Past 2030, UBS Says
Johnson & Johnson's (JNJ) planned acquisition of Ollin Biosciences for up to $3.3 billion is a poten…
17 Nov 2026 Yahoo Finance J&J to Acquire Ollin Biosciences: A Look at Its Recent Buyouts
J&J's $2.2 billion Ollin Biosciences deal adds a promising retinal disease candidate, building on acquisitions.
17 Nov 2026 Yahoo Finance J&J to Boost Ophthalmology Pipeline With $2.2B Ollin Acquisition
JNJ's $2.2 billion Ollin acquisition adds a phase III eye disease candidate to its pipeline, with Blackstone providing $750 million to fund the development.
17 Nov 2026 Yahoo Finance 3 Bulletproof Passive Income Dividend Kings to Buy and Hold Forever
Cancer drugs, detergent, and soda have funded more than 50 straight years of dividend hikes. But a talc settlement, a pending IRS ruling, and rising commodity costs test whether each payout can survive the next shock.
17 Nov 2026 Yahoo Finance Wall Street Analysts Think Johnson & Johnson (JNJ) Is a Good Investment: Is It?
The average brokerage recommendation (ABR) for Johnson & Johnson (JNJ) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
17 Nov 2026 Yahoo Finance Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
17 Nov 2026 Yahoo Finance Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs. Flat Revenue
Johnson & Johnson's revenue has climbed quarter after quarter, while Novo Nordisk's has stayed largely flat apart from one notable jump.
16 Nov 2026 Yahoo Finance Johnson & Johnson (JNJ) Eyes Ollin Biosciences, Is It 19% Overvalued?
Johnson & Johnson (JNJ) is back in focus after reports it is in advanced talks to buy eye drug developer Ollin Biosciences in a deal valued at up to US$3.4b. The Ollin Biosciences headlines land on top of a strong run for Johnson & Johnson, with the share price at US$285.75 and a 30 day share price…
16 Nov 2026 Yahoo Finance Top Analyst Reports for Taiwan Semiconductor, Johnson & Johnson and Palantir
Taiwan Semiconductor, Johnson & Johnson and Palantir headline today's analyst reports, with AI growth, drug pipelines and competitive pressures shaping their outlooks.
16 Nov 2026 Yahoo Finance J&J Pushes Into Retinal Disease With $2.2 Billion Ollin Deal
The deal adds OLN324, a Phase 3 bispecific antibody aimed at two drivers of retinal disease…
16 Nov 2026 Yahoo Finance J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences
The deal sees J&J bolster its pipeline with a bispecific antibody in Phase III development for wAMD and DME.
16 Nov 2026 Yahoo Finance Johnson & Johnson Stocks Edge Higher on $2.2 Billion Ollin Eye Deal
J&J is buying a late-stage retinal disease antibody, and Blackstone will fund its $750 million Phase 3 program.
16 Nov 2026 Yahoo Finance J&J bets $2.2B on Ollin’s vision loss drug
The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.
16 Nov 2026 Yahoo Finance Johnson & Johnson Agrees to Buy Ollin Biosciences in Up to $3.33 Billion Deal
Johnson & Johnson (JNJ) has agreed to acquire eye disease therapy developer Ollin Biosciences in a d…
16 Nov 2026 Yahoo Finance J&J Stock Rallies More Than 10% in a Month: Time to Buy, Sell or Hold?
JNJ's rally reflects stronger earnings and promising drug launches, but MedTech weakness, patent losses and litigation risks remain.
16 Nov 2026 Yahoo Finance Blackstone Life Sciences Announces $750 Million R&D Funding Agreement
CAMBRIDGE, Mass., November 16, 2026--Blackstone announced today that funds managed by Blackstone Life Sciences ("Blackstone") will provide $750 million in development funding to Johnson & Johnson to support the Phase 3 clinical development of OLN324, an investigational therapy for serious retinal…
16 Nov 2026 Yahoo Finance Ollin Biosciences and Its Next-Generation Medicines for Patients with Vision-Threatening Eye Diseases to be Acquired
AUSTIN, Texas, November 16, 2026--Ollin Biosciences, Inc. ("Ollin"), a privately-held clinical-stage biopharmaceutical company developing therapies for serious eye diseases, today announced it has entered into a definitive agreement to be acquired by Johnson & Johnson for $2.2 billion upfront with…
16 Nov 2026 Yahoo Finance Why Is Johnson & Johnson (JNJ) Showcasing New Blood Cancer Data At ASH?
Johnson & Johnson (NYSE:JNJ) unveiled new clinical data across its oncology and immunology pipeline at the 2026 ASH Annual Meeting. The company reported first clinical results for trispecific antibody therapies and new T cell engaging antibodies in blood cancers. Real world analyses in multiple…
16 Nov 2026 Yahoo Finance Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology
NEW BRUNSWICK, N.J., November 16, 2026--Johnson & Johnson (NYSE: JNJ) today announced it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., ("Ollin") a clinical-stage biopharmaceutical company developing therapies for serious eye diseases, for $2.2 billion upfront, with the…
16 Nov 2026 Yahoo Finance ETFs Are Net Sellers of Johnson & Johnson (JNJ) on Thursday
Johnson & Johnson saw $72.5 million in net ETF selling on Thursday.
16 Nov 2026 Yahoo Finance Does Johnson & Johnson Stock's Valuation Make Sense?
For questions about this article or underlying research, email [email protected].
15 Nov 2026 Yahoo Finance J&J in talks to buy eye disease biotech Ollin for $3.4 bln, FT reports
Investing.com-- Johnson & Johnson (NYSE:JNJ) is in advanced talks to acquire privately held eye disease drug developer Ollin Biosciences for up to $3.4 billion, the Financial Times reported on Sunday, citing people familiar with the matter.
14 Nov 2026 Yahoo Finance Coca-Cola and J&J Just Hit Record Highs. A 62-Year-Old Put $300,000 Into Them and Procter & Gamble in 2016. Here’s How Much the Now 72-Year-Old Gets Paid Every Single Month
A 62-year-old split $300,000 across Johnson & Johnson, Procter & Gamble and Coca-Cola on Nov. 14, 2016. Ten years of dividend raises later, here is the monthly check at 72, the cash collected, what the shares are worth after Friday's record highs, the reinvested version, and the federal tax on the…
14 Nov 2026 Yahoo Finance 5 Dividend Stocks to Buy and Hold Forever
These five stocks have proven track records of dividend growth backed by attractive businesses.
13 Nov 2026 Yahoo Finance Did Bipolar Drug Win Just Shift JNJ's Investment Narrative?
Johnson & Johnson reported that its second pivotal Phase 3 trial of Caplyta in bipolar I mania met primary and key secondary endpoints, with clinically meaningful improvements in manic symptoms versus placebo, supporting a planned U.S. regulatory filing. The readout strengthens Johnson & Johnson's…
13 Nov 2026 Yahoo Finance AbbVie or Johnson & Johnson: Only One Gets My Dividend Dollars for the Next 20 Years
Key TakeawaysAbbVie raised its quarterly dividend 5% on Oct. 30, while Johnson & Johnson took a $5…
13 Nov 2026 Yahoo Finance Pfizer or Johnson & Johnson: The One Dividend Stock I’d Hold for the Next 20 Years
Key TakeawaysPfizer yields 6%, more than three times Johnson & Johnson’s 1. 9%, and both companies raised their 2026 guidance this fall.
13 Nov 2026 Yahoo Finance Johnson & Johnson vs. Coca-Cola: Both Have Raised Their Dividends 64 Years Straight. Which Streak Is Safer?
Key TakeawaysJohnson & Johnson (JNJ:NYSE) and Coca-Cola (KO:NYSE) yield 1. 9% and 2…
13 Nov 2026 Yahoo Finance ETFs Are Buying Johnson & Johnson (JNJ) on Nov. 11
ETFs bought $89.7 million of Johnson & Johnson stock on Nov. 11…
12 Nov 2026 Yahoo Finance Why Did AAPL, COST, JNJ Stocks Hit 52-Week Highs Today?
Investors rotated toward defensive stocks amid AI-sector uncertainty.
12 Nov 2026 Yahoo Finance Johnson & Johnson (JNJ) Backs New Cancer Device And Leads $100 Million Depression Bet
Johnson & Johnson (NYSE: JNJ) agreed to invest in Francis Medical to help advance its Vanquish device for prostate cancer treatment. The group also led a US$100 million funding round in Delix Therapeutics to back clinical development of psychedelic inspired depression medicines. Both deals extend…
12 Nov 2026 Yahoo Finance Johnson & Johnson (JNJ) Up 10.4% Since Last Earnings Report: Can It Continue?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
12 Nov 2026 Yahoo Finance J&J leads Francis Medical investment to fund prostate cancer device
With Johnson & Johnson’s support, Francis plans to take its water-vapor therapy device through the premarket approval process.
12 Nov 2026 Yahoo Finance Is There A Risk Hiding In Johnson & Johnson Stock's Earnings?
For questions about this article or underlying research, email [email protected].
12 Nov 2026 Yahoo Finance Johnson & Johnson vs. Procter & Gamble: 64 and 70 Straight Years of Raises. Which Dividend King Pays You More Over the Next Decade?
Key TakeawaysProcter & Gamble yields 2. 7% and Johnson & Johnson 1…
12 Nov 2026 Yahoo Finance State Street Health Care SPDR (XLV) Adds Eli Lilly and Johnson & Johnson on Nov. 10
The fund bought $132.2 million of stock, increasing all 60 of its positions and selling nothing.
11 Nov 2026 Yahoo Finance Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?
The business has undergone major changes in recent years, and these might pay off over the medium term.
11 Nov 2026 Yahoo Finance Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?
Eli Lilly's sales jumped 44.7% last year, while Johnson & Johnson's steadier profile raises a different question for cautious portfolios.
11 Nov 2026 Yahoo Finance SGOV Yields 3.63%. Can Johnson & Johnson or Verizon Pay Retirees More?
One income stream resets every time the Fed moves, while two others depend on a board's vote and a balance sheet. Which payout holds up best over a long retirement, and why might taxes change the answer?
11 Nov 2026 Yahoo Finance J&J funds Francis Medical to seek cancer indication for Vanquish device
Francis Medical’s water vapour ablation system secured FDA clearance for prostate tissue ablation in November 2025, and is now eyeing an oncology expansion.
11 Nov 2026 Yahoo Finance Massachusetts Woman’s Family Awarded $3.3 Million Against Johnson & Johnson in Mesothelioma Case
DALLAS, November 11, 2026--National plaintiffs trial firm Dean Omar Branham Shirley, LLP, (DOBS) has secured a verdict in the amount of $1,914,990 accompanied by court ordered interest of $1,410,541 for a sum total of $3,325,631 against Johnson & Johnson on behalf of the family of Winifred "Missy"…
11 Nov 2026 Yahoo Finance Johnson & Johnson Reports Favorable Data For Bipolar Study
Johnson & Johnson (NYSE:JNJ) reported topline results on Tuesday from Study 452, its second pivotal Phase 3 trial evaluating CAPLYTA (lumateperone) in adults with bipolar I disorder. The therapy met its primary and key secondary endpoints, producing rapid, sustained relief in manic symptoms and…
11 Nov 2026 Yahoo Finance 3 Legacy Health Care Dividend Stocks That Never Go Out of Style
Three health care giants have raised dividends for decades, yet each hides a catch that could shrink or stall a retiree's income. One faces lawsuits, one plans a spinoff, and one raises its payout by a single cent.
11 Nov 2026 Yahoo Finance State Street Health Care SPDR (XLV) Sells Eli Lilly and J&J on Nov. 9
The fund sold $320.2 million of stock, cutting all 60 positions and adding nothing on Monday.
显示更多
股息率 (DY TTM) 1.92%
5年平均股息收益率 2.39%
股息支付比率 53.75%
除息日 公告日期 支付日期 详情
18 Feb 2025 02 Jan 2025 04 Mar 2025 1.24 现金
26 Nov 2024 15 Oct 2024 10 Dec 2024 1.24 现金
27 Aug 2024 17 Jul 2024 10 Sep 2024 1.24 现金
20 May 2024 16 Apr 2024 04 Jun 2024 1.24 现金
16 Feb 2024 02 Jan 2024 05 Mar 2024 1.19 现金
20 Nov 2023 19 Oct 2023 05 Dec 2023 1.19 现金
25 Aug 2023 20 Jul 2023 07 Sep 2023 1.19 现金
22 May 2023 18 Apr 2023 06 Jun 2023 1.19 现金
17 Feb 2023 03 Jan 2023 07 Mar 2023 1.13 现金
21 Nov 2022 19 Oct 2022 06 Dec 2022 1.13 现金
22 Aug 2022 18 Jul 2022 06 Sep 2022 1.13 现金
23 May 2022 19 Apr 2022 07 Jun 2022 1.13 现金
18 Feb 2022 04 Jan 2022 08 Mar 2022 1.06 现金
22 Nov 2021 21 Oct 2021 07 Dec 2021 1.06 现金
23 Aug 2021 19 Jul 2021 07 Sep 2021 1.06 现金
24 May 2021 06 May 2021 08 Jun 2021 1.06 现金
22 Feb 2021 04 Jan 2021 09 Mar 2021 1.01 现金
23 Nov 2020 22 Oct 2020 08 Dec 2020 1.01 现金
24 Aug 2020 20 Jul 2020 08 Sep 2020 1.01 现金
22 May 2020 14 Apr 2020 09 Jun 2020 1.01 现金
24 Feb 2020 02 Jan 2020 10 Mar 2020 0.95 现金
25 Nov 2019 18 Oct 2019 10 Dec 2019 0.95 现金
26 Aug 2019 16 Jul 2019 10 Sep 2019 0.95 现金
24 May 2019 26 Apr 2019 11 Jun 2019 0.95 现金
25 Feb 2019 02 Jan 2019 12 Mar 2019 0.9 现金
26 Nov 2018 18 Oct 2018 11 Dec 2018 0.9 现金
27 Aug 2018 17 Jul 2018 11 Sep 2018 0.9 现金
25 May 2018 26 Apr 2018 12 Jun 2018 0.9 现金
26 Feb 2018 02 Jan 2018 13 Mar 2018 0.84 现金
27 Nov 2017 19 Oct 2017 12 Dec 2017 0.84 现金
25 Aug 2017 17 Jul 2017 12 Sep 2017 0.84 现金
25 May 2017 27 Apr 2017 13 Jun 2017 0.84 现金
24 Feb 2017 03 Jan 2017 14 Mar 2017 0.8 现金
18 Nov 2016 20 Oct 2016 06 Dec 2016 0.8 现金
19 Aug 2016 18 Jul 2016 06 Sep 2016 0.8 现金
20 May 2016 28 Apr 2016 07 Jun 2016 0.8 现金
19 Feb 2016 04 Jan 2016 08 Mar 2016 0.75 现金
20 Nov 2015 22 Oct 2015 08 Dec 2015 0.75 现金
21 Aug 2015 20 Jul 2015 08 Sep 2015 0.75 现金
21 May 2015 23 Apr 2015 09 Jun 2015 0.75 现金
20 Feb 2015 05 Jan 2015 10 Mar 2015 0.7 现金
21 Nov 2014 16 Oct 2014 09 Dec 2014 0.7 现金
22 Aug 2014 21 Jul 2014 09 Sep 2014 0.7 现金
22 May 2014 24 Apr 2014 10 Jun 2014 0.7 现金
21 Feb 2014 02 Jan 2014 11 Mar 2014 0.66 现金
22 Nov 2013 17 Oct 2013 10 Dec 2013 0.66 现金
23 Aug 2013 15 Jul 2013 10 Sep 2013 0.66 现金
23 May 2013 25 Apr 2013 11 Jun 2013 0.66 现金
22 Feb 2013 02 Jan 2013 12 Mar 2013 0.61 现金
23 Nov 2012 17 Oct 2012 11 Dec 2012 0.61 现金
24 Aug 2012 16 Jul 2012 11 Sep 2012 0.61 现金
24 May 2012 26 Apr 2012 12 Jun 2012 0.61 现金
24 Feb 2012 03 Jan 2012 13 Mar 2012 0.57 现金
25 Nov 2011 21 Oct 2011 13 Dec 2011 0.57 现金
26 Aug 2011 18 Jul 2011 13 Sep 2011 0.57 现金
26 May 2011 28 Apr 2011 14 Jun 2011 0.57 现金
25 Feb 2011 03 Jan 2011 15 Mar 2011 0.54 现金
26 Nov 2010 21 Oct 2010 14 Dec 2010 0.54 现金
27 Aug 2010 19 Jul 2010 14 Sep 2010 0.54 现金
27 May 2010 22 Apr 2010 15 Jun 2010 0.54 现金
19 Feb 2010 04 Jan 2010 09 Mar 2010 0.49 现金
20 Nov 2009 22 Oct 2009 08 Dec 2009 0.49 现金
21 Aug 2009 20 Jul 2009 08 Sep 2009 0.49 现金
21 May 2009 23 Apr 2009 09 Jun 2009 0.49 现金
20 Feb 2009 05 Jan 2009 10 Mar 2009 0.46 现金
21 Nov 2008 16 Oct 2008 09 Dec 2008 0.46 现金
22 Aug 2008 21 Jul 2008 09 Sep 2008 0.46 现金
22 May 2008 24 Apr 2008 10 Jun 2008 0.46 现金
22 Feb 2008 02 Jan 2008 11 Mar 2008 0.415 现金
23 Nov 2007 18 Oct 2007 11 Dec 2007 0.415 现金
24 Aug 2007 16 Jul 2007 11 Sep 2007 0.415 现金
24 May 2007 26 Apr 2007 12 Jun 2007 0.415 现金
23 Feb 2007 03 Jan 2007 13 Mar 2007 0.375 现金
24 Nov 2006 19 Oct 2006 12 Dec 2006 0.375 现金
25 Aug 2006 18 Jul 2006 12 Sep 2006 0.375 现金
25 May 2006 27 Apr 2006 13 Jun 2006 0.375 现金
18 Nov 2005 20 Oct 2005 13 Dec 2005 0.33 现金
19 Aug 2005 18 Jul 2005 13 Sep 2005 0.33 现金
13 May 2005 28 Apr 2005 07 Jun 2005 0.33 现金
11 Feb 2005 04 Jan 2005 08 Mar 2005 0.285 现金
12 Nov 2004 22 Oct 2004 07 Dec 2004 0.285 现金
13 Aug 2004 20 Jul 2004 07 Sep 2004 0.285 现金
14 May 2004 22 Apr 2004 08 Jun 2004 0.285 现金
12 Feb 2004 05 Jan 2004 09 Mar 2004 0.24 现金
14 Nov 2003 16 Oct 2003 09 Dec 2003 0.24 现金
15 Aug 2003 22 Jul 2003 09 Sep 2003 0.24 现金
16 May 2003 24 Apr 2003 10 Jun 2003 0.24 现金
13 Feb 2003 06 Jan 2003 11 Mar 2003 0.205 现金
15 Nov 2002 15 Oct 2002 10 Dec 2002 0.205 现金
16 Aug 2002 15 Jul 2002 10 Sep 2002 0.205 现金
17 May 2002 25 Apr 2002 11 Jun 2002 0.205 现金
14 Feb 2002 02 Jan 2002 12 Mar 2002 0.18 现金
16 Nov 2001 18 Oct 2001 11 Dec 2001 0.18 现金
17 Aug 2001 16 Jul 2001 11 Sep 2001 0.18 现金
18 May 2001 26 Apr 2001 12 Jun 2001 0.36 现金
15 Feb 2001 02 Jan 2001 13 Mar 2001 0.32 现金
17 Nov 2000 16 Oct 2000 12 Dec 2000 0.32 现金
18 Aug 2000 17 Jul 2000 12 Sep 2000 0.32 现金
19 May 2000 19 Apr 2000 13 Jun 2000 0.32 现金
11 Feb 2000 03 Jan 2000 07 Mar 2000 0.28 现金
12 Nov 1999 18 Oct 1999 07 Dec 1999 0.28 现金
13 Aug 1999 19 Jul 1999 07 Sep 1999 0.28 现金
14 May 1999 22 Apr 1999 08 Jun 1999 0.28 现金
11 Feb 1999 04 Jan 1999 09 Mar 1999 0.25 现金
13 Nov 1998 19 Oct 1998 08 Dec 1998 0.25 现金
14 Aug 1998 20 Jul 1998 08 Sep 1998 0.25 现金
15 May 1998 23 Apr 1998 09 Jun 1998 0.25 现金
12 Feb 1998 02 Jan 1998 10 Mar 1998 0.22 现金
14 Nov 1997 20 Oct 1997 09 Dec 1997 0.22 现金
15 Aug 1997 21 Jul 1997 09 Sep 1997 0.22 现金
16 May 1997 24 Apr 1997 10 Jun 1997 0.22 现金
13 Feb 1997 02 Jan 1997 11 Mar 1997 0.19 现金
15 Nov 1996 21 Oct 1996 10 Dec 1996 0.19 现金
16 Aug 1996 15 Jul 1996 10 Sep 1996 0.19 现金
17 May 1996 25 Apr 1996 11 Jun 1996 0.38 现金
15 Feb 1996 02 Jan 1996 12 Mar 1996 0.33 现金
10 Nov 1995 16 Oct 1995 05 Dec 1995 0.33 现金
11 Aug 1995 17 Jul 1995 05 Sep 1995 0.33 现金
10 May 1995 27 Apr 1995 06 Jun 1995 0.33 现金
显示更多

每年股息收益率

年份 每年总股息 ($) 频率/年份 收益率 %
2025 1.24 1 0.60
2024 4.91 4 3.40
2023 4.70 4 3.00
2022 4.45 4 2.52
2021 4.19 4 2.45
2020 3.98 4 2.53
2019 3.75 4 2.57
2018 3.54 4 2.74
2017 3.32 4 2.38
2016 3.15 4 2.73
2015 2.95 4 2.87
2014 2.76 4 2.64
2013 2.59 4 2.83
2012 2.40 4 3.42
2011 2.25 4 3.43
2010 2.11 4 3.41
2009 1.93 4 3.00
2008 1.80 4 3.00
2007 1.62 4 2.43
2006 1.13 3 1.70
2005 1.28 4 2.12
2004 1.10 4 1.73
2003 0.925 4 1.79
2002 0.795 4 1.48
2001 1.04 4 1.76
2000 1.24 4 2.36
1999 1.09 4 2.34
1998 0.970 4 2.31
1997 0.850 4 2.58
1996 1.09 4 4.38
1995 0.990 3 4.63
显示更多

近期信号 K线形态与EMA交叉

▼ 看跌吞没 上一个交易日 · 16 Nov
上涨后,阴线实体完全覆盖前一根阳线。看跌反转信号。

AI 技术分析

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票